Replies to post #1334 on Idenix Pharmaceuticals (IDIX)

[ThomasS]

May 08: Expiration of NVS-IDIX standstill agreement.

Dew, haven't you stated in the past that the two companies can mutually agree to invalidate the standstill?

[go seek]

2007-2008 News Flow
added report on IDX899 interaction w/ P450 in 4Q07

Aug 07: 2Q07 financial results (no CC).

Nov 07: Data from selected Tyzeka post-marketing studies at AASLD conference.

Nov 07: 3Q07 financial results and CC.

End 2007: Go/no-go decision on advancing Valtorcitabine (a Tyzeka adjuvant for HBV) to phase-3.

End 2007: File IND for IDX102 or IDX184 2nd-generation HCV nucleoside analogs.

End 2007: Seven-day viral-load data for IDX899 in treatment-naïve HIV.

End 2007: Report on IDX899 interaction w/ P450 in 4Q07

Feb 08: IDX899 data at CROI conference.

Mar 08: 4Q07 financial results and CC with 2008 financial guidance.

May 08: Expiration of NVS-IDIX standstill agreement.

End 2008: File IND for HCV non-nucleoside polymerase inhibitor.

End 2008: File IND for HCV protease inhibitor.